Related Experiment Video
Updated: May 21, 2025
09:31
Evaluation of Stem Cell Therapies in a Bilateral Patellar Tendon Injury Model in Rats
Published on: March 30, 2018
11.1K
Calciphylaxis: ongoing challenges and treatment opportunities with mesenchymal stem cells
Daoxu Wu1,2,3, Shijiu Lu1,2, Jiaying Hu1,2
1Division of Nephrology, Department of Geriatrics, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
Journal of Molecular Cell Biology
|March 17, 2025
Summary
Calciphylaxis, a rare disorder affecting chronic kidney disease patients, involves microvascular calcifications and skin ulcers. Mesenchymal stem cells show promise as a novel therapy for this condition.
Area of Science:
- Nephrology
- Dermatology
- Vascular Biology
Background:
- Calciphylaxis is a rare, progressive disorder causing microvascular calcifications and skin damage, primarily in chronic kidney disease (CKD) patients.
- It leads to nonhealing ulcers and high mortality, with current treatments focusing on multidisciplinary approaches.
- The exact pathogenesis remains unclear, and existing animal models do not fully replicate the human condition.
Purpose of the Study:
- To review current knowledge on calciphylaxis, including epidemiology, risk factors, diagnosis, pathogenesis, and treatment.
- To highlight the limitations in understanding pathogenesis due to scarce animal models.
- To explore novel therapeutic strategies, particularly mesenchymal stem cells (MSCs).
Main Methods:
- Literature review of epidemiological characteristics, risk factors, diagnosis, pathogenesis, animal models, and treatment of calciphylaxis.
- Discussion of diagnostic challenges, including non-uraemic calciphylaxis (NUC) and visceral calciphylaxis.
- Exploration of advanced research systems incorporating artificial intelligence and patient-specific molecular data.
Main Results:
- Calciphylaxis involves dermal microvascular calcifications, microthrombi, and endothelial damage, often progressing rapidly.
- Vascular calcification in CKD does not fully explain calciphylaxis progression, emphasizing the need for further research into its pathogenesis.
- Mesenchymal stem cells (MSCs) exhibit potential therapeutic benefits including regenerative effects, inhibition of vascular calcification, immunomodulation, and improvement of hypercoagulability.
Conclusions:
- Further research is needed to understand calciphylaxis pathogenesis, with improved animal models and AI-driven approaches being crucial.
- Mesenchymal stem cells (MSCs) represent a promising novel therapy for calciphylaxis due to their multifaceted properties.
- Biomarker-guided, safe, effective, and economical MSC strategies warrant consideration for treating this severe disease.
